TNTetsuya Nosaka

Tetsuya Nosaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tetsuya Nosaka has a total of 198 co-authors. Here are the top co-authors by number of shared publications:

  • Junpei Ohtsuka

    Department of Microbiology and Molecular Genetics Mie University Graduate School of Medicine Tsu Japan

    6 shared publications
  • Esteban Cesar Gabazza

    Department of Immunology, Faculty and Graduate School of Medicine, Mie University, Edobashi 2-174, Tsu 514-8507, Mie, Japan

    5 shared publications
  • Ryoichi Ono

    Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Japan

    5 shared publications
  • Atsuro Takeshita

    Department of Diabetes and Endocrinology, Mie University Faculty and Graduate School of Medicine, Tsu, Japan

    4 shared publications
  • Atsushi Tomaru

    Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Japan

    4 shared publications
  • Isaac Cann

    Carl R. Woese Institute for Genomic Biology (Microbiome Metabolic Engineering), University of Illinois Urbana-Champaign, Urbana, USA

    4 shared publications

Latest Publications

  • Open Access

    Sparfloxacin reveals a host–virus dual-target antiviral scaffold against respiratory syncytial virus

    by Yuka Takumi-Tanimukai, Soh Yamamoto, Yurie Yoshida, Tatsuki Takahashi, Akira Takasawa, Akira Katsuyama, Takumi Nishimaki, Haruka Maeda, Katsumi Mizuta, Masashi Idogawa, et al.

    Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness across the lifespan, particularly in infants and older adults. Nonetheless, effective antiviral therapies remain limited. Here, we performed a clinically guided, medium-throughput screening of approved drugs used in pediatric populations and identified sparfloxacin (SPFX), a fluoroquinolone antibiotic, as a mechanistically informative antiviral scaffold. SPFX showed antiviral activity against genetically distinct RSV clinical isolates in vitro, and suppressed RSV infection in a mechanistic mouse model in vivo. Mechanistically, our findings support a host–virus dual-target framework in which SPFX suppresses RSV replication through activity consistent with modulation of viral RNA polymerase function together with a pro-viral HSP70-associated host pathway. Using primary human pediatric airway epithelial cells, we identified SPFX-responsive host factors and observed suppression of HSP70 expression independent of infection. Together, these findings establish SPFX as a mechanistically informative antiviral scaffold and support a host–virus dual-target framework for future RSV therapeutic development.

  • Open Access

    Corisin induces proteostasis stress to drive epithelial injury and pulmonary fibrosis

    by Hajime Fujimoto, Taro Yasuma, Corina N. D’ALessandro-Gabazza, Masaaki Toda, Kota Nishihama, Atsuro Takeshita, Valeria Fridman D’ALessandro, Atsushi Tomaru, Haruko Saiki, Tomohito Okano, et al.

    Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease lacking clarity on the mechanisms linking epithelial injury to fibrotic remodeling. Here, we identify the microbiota-derived corisin as a potent, multifaceted driver of epithelial injury and pulmonary fibrosis. Leveraging targeted DNA sequencing of bronchoalveolar lavage fluid, we provide the first sequence-based identification of corisin in IPF patients and show that functional depletion of native corisin from patient bronchoalveolar lavage fluid abolishes its proapoptotic activity in alveolar epithelial cells. Synthetic corisin readily penetrates epithelial cells, localizes to mitochondria, and induces apoptosis, cellular senescence, and epithelial–mesenchymal transition, effects validated by single-cell transcriptomic analysis. High-throughput protein-interaction screening identifies the ubiquitin–proteasome system as the primary target, demonstrating that corisin enhances proteasome activity and disrupts epithelial proteostasis. Intracellular expression of native corisin recapitulates these cellular pathologies at concentrations relevant to human disease, confirming its high intrinsic potency. Most critically, transgenic mice constitutively expressing native corisin develop spontaneous, progressive pulmonary fibrosis and exhibit exacerbated injury and increased mortality following bleomycin challenge. Collectively, our findings establish corisin as a microbiota-derived effector that directly couples the collapse of epithelial proteostasis to multimechanistic cell-fate dysregulation and fibrotic remodeling, thereby defining a potent and causal microbial–epithelial axis in the pathogenesis of IPF.


  • New insights into JAK2 germline variant-driven stromal cell alterations and proinflammatory bone marrow niche remodeling in myeloproliferative neoplasms

    by Komei Nishimura, Ryoichi Ono, Keiki Nagaharu, Eiko Ohya, Takuya Tsuji, Makoto Ikejiri, Akihide Nakamura, Tetsuya Nosaka, Isao Tawara, Yuka Sugimoto, et al.

  • Open Access

    Microbiota-derived corisin accelerates kidney fibrosis by promoting cellular aging

    by Taro Yasuma, Hajime Fujimoto, Corina N. D’aLessandro-Gabazza, Masaaki Toda, Mei Uemura, Kota Nishihama, Atsuro Takeshita, Valeria Fridman D’aLessandro, Tomohito Okano, Yuko Okano, et al.

    The increasing global prevalence of diabetic nephropathy poses substantial health and economic burdens. Currently, effective anti-fibrotic therapies for managing kidney fibrosis associated with chronic kidney disease are lacking. This study reveals corisin, a microbiota-derived peptide, as a central driver in the progression of diabetic kidney fibrosis. Corisin levels were found to be markedly elevated in the serum of diabetic chronic kidney disease patients relative to healthy controls, with strong correlations to advanced disease stages and declining renal function. In a murine model of kidney fibrosis, corisin levels were similarly heightened, directly contributing to increased inflammation and worsening fibrosis and renal impairment. Notably, the use of a monoclonal anti-corisin antibody significantly reduced nephropathy severity in diabetic mice. Through molecular dynamics simulations and experimental validation, we demonstrated that corisin interacts with human serum albumin, potentially enhancing its renal accumulation and pathological impact. The pathogenic mechanism of corisin involves the acceleration of cellular senescence and the induction of epithelial-mesenchymal transition and apoptosis in kidney cells. These findings underscore the critical role of corisin in progressive diabetic nephropathy and suggest a promising new target for therapeutic intervention.


  • Open Access

    Next Generation RNA/Protein‐Carrying Vector With Pleiotropic Activity

    by Tetsuya Nosaka, Junpei Ohtsuka, Tomomi Ohtsuka, Masayuki Fukumura

    Human parainfluenza virus type 2 (hPIV2), one of the causative agents of infantile common cold, is a non‐segmented negative‐sense RNA virus with a robust gene expression system. It infects recurrently throughout human life without causing severe disease. Because hPIV2 has a viral envelope that can carry ectopic proteins, we developed a non‐propagative RNA/protein‐carrying vector BC‐PIV by deleting the F gene from hPIV2. BC‐PIV can be vigorously proliferated in the stable packaging cell line Vero/BC‐F cells expressing the hPIV2 F gene but not in other cells. BC‐PIV can deliver exogenous gene(s) on a multigenic RNA genome as an inserted gene fragment(s) and simultaneously deliver exogenous protein(s) on its envelope in a membrane‐anchored form. For example, influenza virus M2e protein, Ebola virus GP protein, and severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2) spike protein were shown to be highly expressed in packaging cells and incorporated into the virion. The Ebola virus GP protein and SARS‐CoV‐2 spike protein, each delivered via BC‐PIV, efficiently induced neutralising antibodies against each virus, even after prior treatment with recombinant BC‐PIV in mice and hamsters, respectively. In this review, we describe the properties of BC‐PIV as a promising vaccine vector, and also demonstrate its application as an anti‐tumour virus.


  • Open Access

    Bleomycin-Induced Pulmonary Fibrosis in Transgenic Mice Carrying the Human MUC5B rs35705950 Variant

    by Suphachai Tharavecharak, Hajime Fujimoto, Taro Yasuma, Corina N. D’alessandro-Gabazza, Masaaki Toda, Atsushi Tomaru, Haruko Saiki, Mei Uemura, Yurie Kogue, Toshiyuki Ito, et al.

    Idiopathic pulmonary fibrosis (IPF) is a progressive, often fatal lung disease characterized by tissue scarring and declining lung function. The MUC5B promoter polymorphism rs35705950, a significant genetic predisposition for IPF, paradoxically associates with better survival and slower disease progression than other IPF genotypes. This study investigates the potential paradoxical protective effects of this MUC5B variant in lung fibrosis. For this purpose, we developed a transgenic mouse model overexpressing the human MUC5B rs35705950 variant in the proximal large airways. Lung fibrosis was induced through subcutaneous injection of bleomycin. Results demonstrated significantly reduced lung fibrosis severity in transgenic mice compared to wild-type mice, assessed by trichrome staining, Ashcroft scoring, and hydroxyproline levels. Additionally, transgenic mice showed significantly lower levels of inflammatory cells and cytokines (TNFα, IL-6, IFNγ) and growth factors (PDGF, CTGF, IL-13) in the bronchoalveolar lavage fluid and lung tissues. There was also a significant decrease in mRNA expressions of fibrosis-related markers (periostin, fibronectin, Col1a1). In summary, this study reveals that mucin overexpression related to the MUC5B rs35705950 variant in the large airways significantly attenuates lung fibrosis and inflammatory responses in transgenic mice. These findings suggest that the rs35705950 variant modulates inflammatory and fibrotic responses in the proximal airways, which may contribute to the slower disease progression observed in IPF patients carrying this variant. Our study offers a possible explanation for the paradoxical beneficial effects of the MUC5B variant despite its role as a significant predisposing factor for IPF.


  • Open Access

    Bahcc1 is critical for the aberrant epigenetic program in a mouse model of MLL-ENL–mediated leukemia

    by Akihide Nakamura, Masahiro Masuya, Makoto Shinmei, Isao Tawara, Tetsuya Nosaka, Ryoichi Ono

    In leukemogenesis, genotoxic stress in hematopoietic stem and progenitor cells (HSPCs) drives individual context-dependent programs of malignant transformation. In light of the various differentiation stages of HSPCs based on a recently revised definition using CD150/CD48, our analyses showed that a subpopulation of long-term repopulating HSCs was most susceptible to MLL-ENL–mediated transformation. An analysis of the molecular mechanism identified Bromo-adjacent homology domain and coiled-coil containing 1 (Bahcc1), which encodes a reader molecule of trimethylated histone H3 lysine 27 (H3K27me3), as a candidate gene involved in distinct susceptibility to leukemic transformation. Interestingly, Bahcc1 was previously reported to be highly expressed in acute myeloid leukemia (AML) with an unfavorable prognosis, including some cases of MLL-rearranged AML. We found that MLL-ENL upregulated Bahcc1 through binding to its promoter, and that Bahcc1 was involved in MLL-ENL–mediated immortalization at least partly through repression of H3K27me3-marked Cdkn1c. Analyses using bone marrow transplantation in mice showed that depletion of Bahcc1 suppressed the leukemogenic activity of MLL-ENL. In a public database, high BAHCC1 expression was found to be associated with a poor prognosis in pediatric AML, in which BAHCC1 expression was significantly lower in MLL-AF9-AML than in other MLL-fusion-AML. These findings shed light on the distinct immortalization potential of HSPCs and suggest a novel MLL-fusion-Bahcc1 axis, which may lead to development of molecular targeted therapy against MLL-fusion–mediated leukemia.


  • Open Access

    Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis

    by Corina N. D’aLessandro-Gabazza, Taro Yasuma, Tetsu Kobayashi, Masaaki Toda, Ahmed M. Abdel-Hamid, Hajime Fujimoto, Osamu Hataji, Hiroki Nakahara, Atsuro Takeshita, Kota Nishihama, et al.

    Idiopathic pulmonary fibrosis is an incurable disease of unknown etiology. Acute exacerbation of idiopathic pulmonary fibrosis is associated with high mortality. Excessive apoptosis of lung epithelial cells occurs in pulmonary fibrosis acute exacerbation. We recently identified corisin, a proapoptotic peptide that triggers acute exacerbation of pulmonary fibrosis. Here, we provide insights into the mechanism underlying the processing and release of corisin. Furthermore, we demonstrate that an anticorisin monoclonal antibody ameliorates lung fibrosis by significantly inhibiting acute exacerbation in the human transforming growth factorβ1 model and acute lung injury in the bleomycin model. By investigating the impact of the anticorisin monoclonal antibody in a general model of acute lung injury, we further unravel the potential of corisin to impact such diseases. These results underscore the role of corisin in the pathogenesis of acute exacerbation of pulmonary fibrosis and acute lung injury and provide a novel approach to treating this incurable disease.


  • Open Access

    Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2

    by Junpei Ohtsuka, Masaki Imai, Masayuki Fukumura, Mitsuyo Maeda, Asami Eguchi, Ryoichi Ono, Tadashi Maemura, Mutsumi Ito, Seiya Yamayoshi, Yosky Kataoka, et al.


  • Open Access

    Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models

    by Ryoichi Ono, Masahiro Masuya, Naokazu Inoue, Makoto Shinmei, Satomi Ishii, Yuri Maegawa, Bishnu Devi Maharjan, Naoyuki Katayama, Tetsuya Nosaka

    The Ten Eleven Translocation 1 (TET1) gene encodes an epigenetic modifying molecule that is involved in demethylation of 5-methylcytosine. In hematological malignancies, loss-of-function mutations of TET2, which is one of the TET family genes including TET1, are frequently found, while the mutations of TET1 are not. However, clinical studies have revealed that TET1 is highly expressed in some cases of the hematological malignancies including acute myeloid leukemia. Indeed, studies by mouse models using conventional Tet1 knockout mice demonstrated that Tet1 is involved in myeloid leukemogenesis by Mixed Lineage Leukemia (MLL) fusion gene or TET2 mutant. Meanwhile, the other study showed that Tet1 is highly expressed in hematopoietic stem cells (HSCs), and that deletion of Tet1 in HSCs enhances potential self-renewal capacity, which is potentially associated with myeloid leukemogenesis. To examine the role of Tet1 in myeloid leukemogenesis more precisely, we generated novel conditional Tet1-knockout mice, which were used to generate the compound mutant mice by crossing with the inducible MLL-ENL transgenic mice that we developed previously. The leukemic immortalization in vitro was not critically affected by conditional ablation of Tet1 in HSCs with the induced expression of MLL-ENL or in hematopoietic progenitor cells retrovirally transduced with MLL-ENL. In addition, the leukemic phenotypes caused by the induced expression of MLL-ENL in vivo was not also critically affected in the compound mutant mouse model by conditional ablation of Tet1, although we found that the expression of Evi1, which is one of critical target genes of MLL fusion gene, in tumor cells was remarkably low under Tet1-ablated condition. These results revealed that Tet1 was dispensable for the myeloid leukemogenesis by MLL-ENL, suggesting that the therapeutic application of Tet1 inhibition may need careful assessment.